Quality of life benefits from arrhythmia ablation: A longitudinal study using the C-CAP questionnaire and EQ5D.


Journal

Pacing and clinical electrophysiology : PACE
ISSN: 1540-8159
Titre abrégé: Pacing Clin Electrophysiol
Pays: United States
ID NLM: 7803944

Informations de publication

Date de publication:
06 2019
Historique:
received: 10 09 2018
revised: 28 02 2019
accepted: 25 03 2019
pubmed: 2 4 2019
medline: 18 3 2020
entrez: 2 4 2019
Statut: ppublish

Résumé

To investigate long-term efficacy of cardiac ablation for symptomatic arrhythmia by gathering generic and arrhythmia-related quality of life data using patient-reported outcome measures before and after ablation. Consecutive patients undergoing cardiac ablation procedures at three sites in the United Kingdom were enrolled (n = 561). Data were collected at baseline, at 8-16 weeks, and 12 months after the ablation with responses from 390 patients received at all three time points. Nonparametric tests were used to identify any changes in patient outcomes due to nonnormal data. There were significant improvements in symptom severity, impact on life scores, EQ-5D-5L indices, and visual analogue score (VAS) scores at pre- versus 3 months and at preablation versus 1 year. Impact on life score showed additional improvement at 1 year versus 3 months, while improvements in symptom severity, EQ-5D-5L indices, and VAS scores continued to be maintained between 3 months and 1 year. Cardiac ablation provides patients with arrhythmias relief from symptoms, and results in an improvement in quality of life. Improvements observed at 3 months are maintained at 1 year follow-up. Questions remain regarding the long-term efficacy of cardiac ablation. We enrolled 561 consecutive patients undergoing ablation procedures at three UK sites. Data were collected at baseline, and at 3 and 12 months. Improvement in symptoms was reported following treatment, with patients continuing to maintain or show continued improvement at 1 year.

Autres résumés

Type: Publisher (spa)
Questions remain regarding the long-term efficacy of cardiac ablation. We enrolled 561 consecutive patients undergoing ablation procedures at three UK sites. Data were collected at baseline, and at 3 and 12 months. Improvement in symptoms was reported following treatment, with patients continuing to maintain or show continued improvement at 1 year.

Identifiants

pubmed: 30933375
doi: 10.1111/pace.13675
pmc: PMC6850751
doi:

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

705-711

Informations de copyright

© 2019 The Authors. Pacing and Clinical Electrophysiology published by Wiley Periodicals, Inc.

Références

Vasc Health Risk Manag. 2014;10:1-12
pubmed: 24379678
Europace. 2017 Mar 1;19(3):465-511
pubmed: 27856540
J Atr Fibrillation. 2013 Aug 31;6(2):849
pubmed: 28496874
J Interv Card Electrophysiol. 2017 Apr;48(3):291-298
pubmed: 28220279
J Clin Oncol. 2014 May 10;32(14):1480-501
pubmed: 24711559
J Am Heart Assoc. 2013 Mar 18;2(2):e004549
pubmed: 23537812
Eur Spine J. 2016 Jan;25(1):282-286
pubmed: 26208938
Gynecol Oncol. 2015 Mar;136(3):429-39
pubmed: 25448486
Qual Life Res. 2016 Jun;25(6):1571-83
pubmed: 26659900
Am Heart J. 2017 Mar;185:59-66
pubmed: 28267476
BMJ. 2013 Sep 06;347:f5277
pubmed: 24014443
Pacing Clin Electrophysiol. 2019 Jun;42(6):705-711
pubmed: 30933375
Hip Int. 2014 Sep-Oct;24(5):465-72
pubmed: 24970318
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777

Auteurs

James M Evans (JM)

Cedar, Cardiff & Vale University Health Board, Cardiff Medicentre, Heath Park, Cardiff, UK.

Kathleen L Withers (KL)

Cedar, Cardiff & Vale University Health Board, Cardiff Medicentre, Heath Park, Cardiff, UK.

Mauro Lencioni (M)

University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, Birmingham, UK.

Grace Carolan-Rees (G)

Cedar, Cardiff & Vale University Health Board, Cardiff Medicentre, Heath Park, Cardiff, UK.

Kathryn A Wood (KA)

Emory University School of Nursing, Atlanta, Georgia.

Hannah Patrick (H)

National Institute for Health and Care Excellence, London, UK.

Michael Griffith (M)

University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, Birmingham, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH